Physiologically‐based pharmacokinetic modeling of the drug-drug interaction between ivacaftor and lefamulin in cystic fibrosis patients

• Asıl Yazarlar: Magali Amiel (Yazar), Alice Ke (Yazar), Steven P. Gelone (Yazar), Hannah M. Jones (Yazar), Wolfgang Wicha (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Wiley, 2024-04-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Lefamulin is being evaluated as a treatment for bacterial exacerbations in cystic fibrosis (CF). Ivacaftor is approved for the treatment of patients with CF. Lefamulin is a moderate CYP3A inhibitor and co‐administration with ivacaftor may result in a drug-drug interaction (DDI). A CF popula...